A phase II study of high‐dose estrogens (diethylstilbestrol diphosphate) in prostate cancer

Dennis L. Citrin; Merrill S. Kies; Carl‐Bertil ‐B Wallemark; Jan Khandekar; Edward Kaplan; Fernando Camacho; Richard Lind

doi:10.1002/1097-0142(19850801)56:3<457::AID-CNCR2820560307>3.0.CO;2-7

A phase II study of high‐dose estrogens (diethylstilbestrol diphosphate) in prostate cancer

Dennis L. Citrin
, Merrill S. Kies
, Carl‐Bertil ‐B Wallemark
, Jan Khandekar
, Edward Kaplan
, Fernando Camacho
, Richard Lind

Oncology

Research output: Contribution to journal › Article › peer-review

26 Scopus citations

Abstract

Twenty‐five patients with metastatic prostate cancer resistant to primary hormone therapy, received high‐dose intravenous diethylstilbestrol diphosphate (Stilphostrol [Miles Pharm], DES‐P) in a Phase II study using established response criteria. Objective response rate was 17%, while 22% of the patients were subjectively improved. Moderate gastrointestinal toxicity was reported in 10 patients (40%). Thromboembolic complications were seen in 2 (8%). The role of high‐dose Stilphostrol in the treatment of hormone‐resistant prostate cancer is limited.

Original language	English (US)
Pages (from-to)	457-460
Number of pages	4
Journal	Cancer
Volume	56
Issue number	3
DOIs	https://doi.org/10.1002/1097-0142(19850801)56:3<457::AID-CNCR2820560307>3.0.CO;2-7
State	Published - Aug 1 1985

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1002/1097-0142(19850801)56:3<457::AID-CNCR2820560307>3.0.CO;2-7

Cite this

@article{e1b40addd22b45f98a9d193da7b03fb3,

title = "A phase II study of high‐dose estrogens (diethylstilbestrol diphosphate) in prostate cancer",

abstract = "Twenty‐five patients with metastatic prostate cancer resistant to primary hormone therapy, received high‐dose intravenous diethylstilbestrol diphosphate (Stilphostrol [Miles Pharm], DES‐P) in a Phase II study using established response criteria. Objective response rate was 17\%, while 22\% of the patients were subjectively improved. Moderate gastrointestinal toxicity was reported in 10 patients (40\%). Thromboembolic complications were seen in 2 (8\%). The role of high‐dose Stilphostrol in the treatment of hormone‐resistant prostate cancer is limited.",

author = "Citrin, \{Dennis L.\} and Kies, \{Merrill S.\} and Wallemark, \{Carl‐Bertil ‐B\} and Jan Khandekar and Edward Kaplan and Fernando Camacho and Richard Lind",

year = "1985",

month = aug,

day = "1",

doi = "10.1002/1097-0142(19850801)56:3<457::AID-CNCR2820560307>3.0.CO;2-7",

language = "English (US)",

volume = "56",

pages = "457--460",

journal = "Cancer",

issn = "0008-543X",

publisher = "John Wiley and Sons Inc.",

number = "3",

}

TY - JOUR

T1 - A phase II study of high‐dose estrogens (diethylstilbestrol diphosphate) in prostate cancer

AU - Citrin, Dennis L.

AU - Kies, Merrill S.

AU - Wallemark, Carl‐Bertil ‐B

AU - Khandekar, Jan

AU - Kaplan, Edward

AU - Camacho, Fernando

AU - Lind, Richard

PY - 1985/8/1

Y1 - 1985/8/1

N2 - Twenty‐five patients with metastatic prostate cancer resistant to primary hormone therapy, received high‐dose intravenous diethylstilbestrol diphosphate (Stilphostrol [Miles Pharm], DES‐P) in a Phase II study using established response criteria. Objective response rate was 17%, while 22% of the patients were subjectively improved. Moderate gastrointestinal toxicity was reported in 10 patients (40%). Thromboembolic complications were seen in 2 (8%). The role of high‐dose Stilphostrol in the treatment of hormone‐resistant prostate cancer is limited.

AB - Twenty‐five patients with metastatic prostate cancer resistant to primary hormone therapy, received high‐dose intravenous diethylstilbestrol diphosphate (Stilphostrol [Miles Pharm], DES‐P) in a Phase II study using established response criteria. Objective response rate was 17%, while 22% of the patients were subjectively improved. Moderate gastrointestinal toxicity was reported in 10 patients (40%). Thromboembolic complications were seen in 2 (8%). The role of high‐dose Stilphostrol in the treatment of hormone‐resistant prostate cancer is limited.

UR - https://www.scopus.com/pages/publications/0021840733

UR - https://www.scopus.com/pages/publications/0021840733#tab=citedBy

U2 - 10.1002/1097-0142(19850801)56:3<457::AID-CNCR2820560307>3.0.CO;2-7

DO - 10.1002/1097-0142(19850801)56:3<457::AID-CNCR2820560307>3.0.CO;2-7

M3 - Article

C2 - 4005808

AN - SCOPUS:0021840733

SN - 0008-543X

VL - 56

SP - 457

EP - 460

JO - Cancer

JF - Cancer

IS - 3

ER -

A phase II study of high‐dose estrogens (diethylstilbestrol diphosphate) in prostate cancer

Abstract

UN SDGs

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this